﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 10:37:46 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Granarium Technologies raises EUR 1 million to commercialise the world’s first renewable, affordable supercapacitors for grid stability and industrial reliability</title><link>https://news.cision.com/vtt-info/r/granarium-technologies-raises-eur-1-million-to-commercialise-the-world-s-first-renewable--affordable,c4359154</link><guid isPermaLink="false">cision5379449</guid><description><![CDATA[Press release 9 June 2026
The VTT-originating startup Granarium Technologies is commercialising nanocellulose-based energy storage technology that upcycles waste wood and agro residues for fast-response power storage with significantly lower production costs and environmental impact compared to conventional solutions.
Granarium Technologies (https://www.granariumtech.com/) (Granarium), a deep-tech energy startup originating from VTT, has raised over EUR 1 million in total funding, comprising a pre-seed round led by BSV Ventures joint by Beamline, with participation from FiBAN (Finnish]]></description><pubDate>Tue, 09 Jun 2026 05:00:00 GMT</pubDate></item><item><title>Better cancer care on the horizon thanks to new blood analysis method</title><link>https://news.cision.com/chalmers/r/better-cancer-care-on-the-horizon-thanks-to-new-blood-analysis-method,c4358108</link><guid isPermaLink="false">cision5379465</guid><description><![CDATA[[image] 

Blood tests have proved to be a promising tool for detecting and monitoring cancer. Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have now developed a new method that makes it possible to analyse samples containing as little as 5 per cent cancer DNA in the blood, compared with the 15–20 per cent required today. This method could lead to better cancer care and improved monitoring of tumour progression.

Analysing changes in tumour DNA using blood tests is a technique that is being explored in several clinical trials worldwide.]]></description><pubDate>Tue, 09 Jun 2026 05:00:00 GMT</pubDate></item><item><title>Diamyd Medical provides update on ongoing Activities</title><link>https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-provides-update-on-ongoing-activities,c4358253</link><guid isPermaLink="false">cision5378193</guid><description><![CDATA[Diamyd Medical today announced that it, as part of an ongoing strategic review, has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations to invest into various business opportunities. Whilst implementing several cost reduction steps, the Company is structuring its approach for evaluating these opportunities with the aim to maximize value for its shareholders.

“Considering the shock with the yet unexplained failure of our Phase-3 study with retogatein, which brought a dramatic fall in the Company’s share value, times are]]></description><pubDate>Fri, 05 Jun 2026 06:30:00 GMT</pubDate></item><item><title>Physics-trained digital ‘super-brain’ speeds up technology development</title><link>https://news.cision.com/chalmers/r/physics-trained-digital--super-brain--speeds-up-technology-development,c4355202</link><guid isPermaLink="false">cision5377260</guid><description><![CDATA[[image] Illustration: Chalmers University of Technology | Viktor Lilja

Studying physics can be very useful – even when it comes to machine learning. A digital ‘super-brain’ with built-in knowledge of the fundamental laws of nature can speed up the development of optical components for everything from quantum computers to eyeglass or camera lenses according to a new study from Chalmers University of Technology in Sweden.

“When we fed the super-brain information about the laws of physics, it immediately got much smarter. Our calculations now take one tenth of the time previously]]></description><pubDate>Thu, 04 Jun 2026 05:00:00 GMT</pubDate></item><item><title>‘Baked’, printed, ready – premiere of architecture made from yeast</title><link>https://news.cision.com/chalmers/r/baked--printed--ready--premiere-of-architecture-made-from-yeast,c4356573</link><guid isPermaLink="false">cision5375814</guid><description><![CDATA[[image] New and renewable architecture made from baker's yeast. Image: Chalmers University of Technology | Henrik Sandsjö.

Researchers at Chalmers University of Technology, Sweden, have developed a new, entirely bio-based material from a somewhat unexpected ingredient: yeast. The material is 3D printed and customised for use in architectural and interior design elements that are currently made from non-renewable or fossil-based materials, such as plaster, plastic or synthetic textiles. These may be daylight modulating and sunlight protecting screens, room partitions or wall systems.]]></description><pubDate>Wed, 03 Jun 2026 05:00:00 GMT</pubDate></item><item><title>QScale: New signal technology is being developed in Finland to scale quantum applications</title><link>https://news.cision.com/vtt-info/r/qscale--new-signal-technology-is-being-developed-in-finland-to-scale-quantum-applications,c4355947</link><guid isPermaLink="false">cision5375086</guid><description><![CDATA[The QScale joint project coordinated by VTT with Tampere and Aalto Universities has received funding from Business Finland's prestigious Rise to Challenge Programme. In the project, researchers are developing a radical improvement in the energy efficiency and scalability of quantum computers through optical control and ultra-precise signal technology based on quantum phenomena. The anticipated breakthrough of quantum technologies into societally impactful applications still requires major research openings such as QScale.
In theory, quantum computers are known to be capable of calculations]]></description><pubDate>Tue, 02 Jun 2026 06:30:00 GMT</pubDate></item><item><title>Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab</title><link>https://news.cision.com/lytix-biopharma-asa/r/lytix-biopharma-reports-phase-ii-data-in-melanoma-and-triple-negative-breast-cancer-for-ruxotemitide,c4355592</link><guid isPermaLink="false">cision5373967</guid><description><![CDATA[Oslo, Norway, 1 June 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that clinical data evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma and metastatic triple-negative breast cancer (TNBC) has been  presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA.

The poster, entitled "Safety and Efficacy of Intratumoral (IT) Ruxotemitide (LTX-315)]]></description><pubDate>Mon, 01 Jun 2026 05:07:25 GMT</pubDate></item><item><title>Spermosens publishes annual report for the financial year 2025</title><link>https://news.cision.com/spermosens/r/spermosens-publishes-annual-report-for-the-financial-year-2025,c4354810</link><guid isPermaLink="false">cision5372764</guid><description><![CDATA[Spermosens hereby announces that the annual report for 2025 is now available for download on the company's website, www.spermosens.com. The annual report is also attached as a PDF to this press release. Please note that this version is an English translation of the official Swedish annual report (Årsredovisning) and has not been audited.

As previously announced, the Annual General Meeting will be held on 18 June 2026.

In 2025, Spermosens successfully completed its clinical study at the Reproductive Medicine Center (RMC) in Malmö ahead of schedule. The study demonstrated a]]></description><pubDate>Thu, 28 May 2026 13:45:47 GMT</pubDate></item><item><title>Spermosens publicerar årsredovisning för räkenskapsåret 2025</title><link>https://news.cision.com/spermosens/r/spermosens-publicerar-arsredovisning-for-rakenskapsaret-2025,c4354754</link><guid isPermaLink="false">cision5372759</guid><description><![CDATA[Spermosens meddelar härmed att årsredovisningen för 2025 nu finns tillgänglig för nedladdning på bolagets webbplats, www.spermosens.com. Årsredovisningen bifogas även som PDF till detta pressmeddelande.

Som tidigare meddelats hålls årsstämman den 18 juni 2026.

Under 2025 slutförde Spermosens framgångsrikt sin kliniska studie vid Reproduktionsmedicinskt centrum (RMC) i Malmö, tidigare än planerat. Studien visade en statistiskt signifikant korrelation mellan spermiernas bindningsförmåga och fertiliseringsgrad vid IVF, vilket bekräftade det diagnostiska värdet av JUNO-Checked. Bolagets]]></description><pubDate>Thu, 28 May 2026 13:39:35 GMT</pubDate></item><item><title>First Quarter Report Q1-2026</title><link>https://news.cision.com/cessatech/r/first-quarter-report-q1-2026,c4354319</link><guid isPermaLink="false">cision5372241</guid><description><![CDATA[The Company has advanced well with its planned activities

  ·
Continued progress towards US launch of CT001

  ·
Regulatory review progressing with EMA following MAA submission for CT001

  ·
Clinical data from CT001 study 0202 presented at Society for Pediatric Pain Medicine (SPPM) 13th Annual Meeting

  ·
Strengthened intellectual property portfolio with additional patents granted in key markets
Copenhagen, Denmark - 28 May 2026 - Cessatech A/S (“Cessatech” or the “Company”), a late-stage paediatric specialty company developing and commercializing non-invasive hospital]]></description><pubDate>Thu, 28 May 2026 06:30:00 GMT</pubDate></item><item><title>Good managers can be as important as the entire team</title><link>https://news.cision.com/handelshogskolan-vid-goteborgs-universitet/r/good-managers-can-be-as-important-as-the-entire-team,c4353742</link><guid isPermaLink="false">cision5371171</guid><description><![CDATA[A good manager can be just as important to a company’s performance as the combined productive capacity of its employees. This is shown in a new international study, published in The Quarterly Journal of Economics. The study also shows that those who are most eager to become managers are not necessarily the best suited to the role.
Research has previously shown that leadership plays an important role in organisational performance. Good managers can increase productivity by monitoring work, allocating tasks effectively and motivating employees. At the same time, it has been difficult to]]></description><pubDate>Wed, 27 May 2026 07:43:12 GMT</pubDate></item><item><title>Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia</title><link>https://news.cision.com/dbp/r/double-bond-pharmaceutical-submits-abstract-with-final-rwe-data-for-temodex-to-the-sno-meeting-in-ph,c4352795</link><guid isPermaLink="false">cision5369566</guid><description><![CDATA[Double Bond Pharmaceutical International AB (publ) (“DBP”) today announces that a scientific abstract based on final clinical data from the company's extensive Real-World Evidence (RWE) study of Temodex has been submitted for review to the scientific committee of the Society for Neuro-Oncology (SNO), ahead of the annual meeting in Philadelphia, USA.

The abstract presents the final results of a retrospective cohort study encompassing a total of 375 patients who underwent surgical resection for malignant primary brain tumors. The purpose of the study was to evaluate the clinical efficacy]]></description><pubDate>Mon, 25 May 2026 12:45:54 GMT</pubDate></item><item><title>Swedish Origami Technique Turns Drone Airports into Flat Packs – Meet STILPOD: Innovative IKEA inspired solution for Aviation</title><link>https://news.cision.com/stilfold-ab/r/swedish-origami-technique-turns-drone-airports-into-flat-packs---meet-stilpod--innovative-ikea-inspi,c4352451</link><guid isPermaLink="false">cision5368863</guid><description><![CDATA[The aircraft of the future are here. The places to land them are not. Today, Swedish design technology company STILFOLD launches STILPOD: the world's first software-defined vertiport. Folded from recycled aluminum, shipped flat in a single standard container, and operational in hours rather than months, STILPOD cuts the embodied carbon of conventional concrete vertiports by 81 percent and leaves zero permanent footprint when uninstalled. After three years of validated development with RISE and Advanced Air Mobility under Sweden's Vinnova iPOD program, STILFOLD is now opening the technology]]></description><pubDate>Mon, 25 May 2026 04:41:34 GMT</pubDate></item><item><title>Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company</title><link>https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-announces-that-niklas-axelsson-has-decided-to-leave-his-position-as-cfo-to-take-on-a-,c4351809</link><guid isPermaLink="false">cision5368124</guid><description><![CDATA[A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person. 

"Although Niklas has worked for Diamyd for a relatively short period, he has left a mark on the organization. I want to express gratitude on behalf of the company – especially regarding the role he played in our most recent fund raising – and wish him success in his continued career," says Anders Essen-Möller, CEO of Diamyd Medical.

About Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for]]></description><pubDate>Fri, 22 May 2026 06:30:00 GMT</pubDate></item><item><title>Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances</title><link>https://news.cision.com/lytix-biopharma-asa/r/lytix-biopharma-q1-2026--clinical-development-priorities-on-track-as-registrational-path-planning-ad,c4351294</link><guid isPermaLink="false">cision5367114</guid><description><![CDATA[Oslo, Norway, May 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today releases its results for the first quarter of 2026.

 

Lytix continued to execute on its established development strategy during the first quarter and post-quarter-end period, with progress across its lead asset ruxotemitide and broader oncolytic molecule platform. Clinical development priorities for 2026 and 2027 remain on track, with registrational path planning advancing for ruxotemitide in neoadjuvant melanoma.

 

Ruxotemitide is supported by a strong and consistent clinical foundation across]]></description><pubDate>Thu, 21 May 2026 05:05:00 GMT</pubDate></item><item><title>Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use</title><link>https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-receives-gmp-certification-and-manufacturing-authorization-for-biological-investigati,c4350560</link><guid isPermaLink="false">cision5366407</guid><description><![CDATA[Diamyd Medical today announced a significant advancement in the company’s operations related to the manufacturing of biological medicines (biologics). The company has now received GMP (Good Manufacturing Practice) certification as well as manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products for human use.

The certification and authorization confirm that Diamyd Medical’s manufacturing facility complies with current regulatory requirements and international quality standards for pharmaceutical production.]]></description><pubDate>Wed, 20 May 2026 06:30:00 GMT</pubDate></item><item><title>NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)</title><link>https://news.cision.com/spermosens/r/notice-of-annual-general-meeting-2026-in-spermosens-ab--publ-,c4349453</link><guid isPermaLink="false">cision5364357</guid><description><![CDATA[The shareholders of Spermosens AB (publ), reg. no. 559179-0380, are hereby invited to attend the Annual General Meeting on Thursday, 18 June 2026 at 10:00 a.m. at Medicon Village (The Spark), Scheeletorget 1, Lund, Sweden.

 

Right to participate and notice of participation

Shareholders wishing to participate in the Annual General Meeting must:

  · be registered as shareholders in the share register maintained by Euroclear Sweden AB on Wednesday, 10 June 2026; and
  · notify the company of their intention to participate no later than Friday, 12 June 2026, in writing to]]></description><pubDate>Mon, 18 May 2026 07:14:39 GMT</pubDate></item><item><title>KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)</title><link>https://news.cision.com/spermosens/r/kallelse-till-arsstamma-2026-i-spermosens-ab--publ-,c4349443</link><guid isPermaLink="false">cision5364354</guid><description><![CDATA[Aktieägarna i Spermosens AB, org. nr. 559179-0380, kallas härmed till årsstämma torsdagen den 18 juni 2026 kl. 10.00 på Medicon Village (The Spark), Scheeletorget 1, i Lund.

 

Rätt att delta och anmälan

Aktieägare som önskar delta i bolagsstämman ska

  · vara upptagen som aktieägare i den av Euroclear Sweden AB förda aktieboken onsdagen den 10 juni 2026, och
  · anmäla sig till bolaget senast fredagen den 12 juni 2026, skriftligen till Spermosens AB, Medicon Village, Scheeletorget 1, 223 81 Lund (märk brevet ”Årsstämma 2026”) eller per e-post till adressen info@spermosens.com.]]></description><pubDate>Mon, 18 May 2026 07:11:29 GMT</pubDate></item><item><title>Five early warning signs of research misconduct</title><link>https://news.cision.com/chalmers/r/five-early-warning-signs-of-research-misconduct,c4348333</link><guid isPermaLink="false">cision5364122</guid><description><![CDATA[[image]

Research misconduct may leave traces in the text itself, not only in how the research is conducted, suggests a new study from Chalmers University of Technology, Sweden. By analysing scientific articles later retracted for misconduct, the researchers identified five recurring rhetorical “warning signs” that can indicate when a study is designed to appear credible despite unreliable foundations.

The findings could make misconduct detection more tangible and support training for doctoral students and early-career researchers. The study suggests that working with authentic]]></description><pubDate>Mon, 18 May 2026 05:00:00 GMT</pubDate></item><item><title>Lytix Biopharma: Invitation to the Q1 2026 Results Presentation</title><link>https://news.cision.com/lytix-biopharma-asa/r/lytix-biopharma--invitation-to-the-q1-2026-results-presentation,c4348989</link><guid isPermaLink="false">cision5363698</guid><description><![CDATA[Oslo, Norway, May 15, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) will release its first quarter 2026 financial results on Thursday, May 21th, 2026.

Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji  where they will discuss the results and provide key insights.

Date: Thursday, May 21th, 2026

Time: 14:00 CET

Q&A Session:

We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.

Webcast Details:

The]]></description><pubDate>Fri, 15 May 2026 08:23:00 GMT</pubDate></item><item><title>EU rules could make fossil-free aviation fuels unnecessarily expensive and energy-intensive</title><link>https://news.cision.com/chalmers/r/eu-rules-could-make-fossil-free-aviation-fuels-unnecessarily-expensive-and-energy-intensive,c4348579</link><guid isPermaLink="false">cision5363280</guid><description><![CDATA[[image]

EU regulations risk leading to inefficient use of biomass for production of sustainable aviation fuel, according to a study from Chalmers University of Technology. Image: CC BY Gustavo Ramirez/CC0

 

The effects of the Iran war on the oil market have brought renewed attention to the EU’s plans for domestic production of fossil-free aviation fuels. But EU rules for synthetic aviation fuels risk steering development towards production pathways that are both more expensive and more energy-intensive than necessary – making it harder to meet climate targets. This is shown in a]]></description><pubDate>Thu, 14 May 2026 06:00:00 GMT</pubDate></item><item><title>Smart AI gives electric vehicle batteries 23 per cent longer life – without increasing the charging time</title><link>https://news.cision.com/chalmers/r/smart-ai-gives-electric-vehicle-batteries-23-per-cent-longer-life---without-increasing-the-charging-,c4346458</link><guid isPermaLink="false">cision5361186</guid><description><![CDATA[[image]

Fast charging shortens the life of vehicle batteries, but is necessary on longer journeys with electric vehicles. Researchers at Chalmers University of Technology, Sweden, have now developed a new AI method that adapts fast charging to the health of the battery. Their study shows that battery life can be increased by almost 23 per cent without extending the charging time. All that is required is an update of the vehicle’s software.

When individuals or companies consider acquiring electric vehicles, the possibility of fast charging is an important factor.

“For taxis or heavy]]></description><pubDate>Tue, 12 May 2026 05:00:00 GMT</pubDate></item><item><title>Spermosens AB (publ) to Host Live Q&amp;A Webcast on 19 May 2026</title><link>https://news.cision.com/spermosens/r/spermosens-ab--publ--to-host-live-q-a-webcast-on-19-may-2026,c4347317</link><guid isPermaLink="false">cision5361003</guid><description><![CDATA[Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live Q&A webcast on Tuesday, 19 May 2026, at 12:00 CET. CEO Tore Duvold will address questions regarding the Company's recent announcements
The session is organised as a dedicated Q&A to provide shareholders and other stakeholders with the opportunity to engage directly with the Company's CEO. The webcast follows the publication of the Company's Q1 2026 report and forms part of Spermosens' commitment to regular investor engagement, with Q&A sessions typically held approximately one week after the]]></description><pubDate>Mon, 11 May 2026 13:59:07 GMT</pubDate></item><item><title>Diamyd Medical provides an update on strategic review and financial position</title><link>https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-provides-an-update-on-strategic-review-and-financial-position,c4346836</link><guid isPermaLink="false">cision5360586</guid><description><![CDATA[Diamyd Medical today announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.

Strategic review update
The initial review phase has resulted in the identification of a short list of potential counterparties, and the Company will now proceed with a focused evaluation of these.

As part of the review, Diamyd Medical is also evaluating strategic alternatives for its biomanufacturing facility in Umeå including potential stand-alone opportunities, or a divestment.

With respect to retogatein (]]></description><pubDate>Mon, 11 May 2026 06:30:00 GMT</pubDate></item></channel></rss>